What is William Blair’s Forecast for TWST Q2 Earnings?

Twist Bioscience Co. (NASDAQ:TWST) – Equities research analysts at William Blair issued their Q2 2026 earnings per share estimates for Twist Bioscience in a note issued to investors on Tuesday, February 4th. William Blair analyst M. Larew expects that the company will post earnings per share of ($0.41) for the quarter. The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.27) per share.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.75) EPS.

TWST has been the subject of several other reports. Barclays cut their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday. Robert W. Baird boosted their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday. Scotiabank increased their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research report on Tuesday. Finally, Wolfe Research started coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus target price of $53.80.

Twist Bioscience Price Performance

TWST stock opened at $52.02 on Wednesday. The firm has a 50 day simple moving average of $48.63 and a two-hundred day simple moving average of $46.21. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Van ECK Associates Corp grew its holdings in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience in the third quarter worth $34,000. Signaturefd LLC raised its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience during the third quarter valued at $95,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares in the last quarter.

Insider Buying and Selling at Twist Bioscience

In other news, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares in the company, valued at approximately $4,762,752.96. This trade represents a 5.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 7,968 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $382,464.00. Following the transaction, the chief executive officer now directly owns 581,584 shares in the company, valued at $27,916,032. This trade represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,707 shares of company stock valued at $2,343,623 in the last quarter. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.